Právní předpis byl sestaven k datu 20.12.2013.
Zobrazené znění právního předpisu je účinné od 20.12.2013 do 19.09.2014.
98
XXXXXXX
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,
xxxxxx xx xxxx x xxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 58/2007 Xx. x. s. x x. 46/2008 Xx. x. s. x xxxxxxxxx xxxxxxx Ministerstva xxxxxxxxxxxx xxxx x. 97/2012 Xx. m. x. x Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx
Xxxxxxxxxxxx xxxxxxxxxxxx věcí xxxxxxx, že dne 12. xxxxxxxxx 2012 xxxx xxxxxxxxx ředitelkou XXXXXX xxxxxxxx xxxxxxxxx xxxxxx xxxxx Xxxxxxx X - Seznamu xxxxxxxxxx xxxxx a xxxxx - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx úmluvy xxxxx xxxxxxx xx xxxxxx1).
X xxxxx xxxxxx Xxxxxxx X xxxxxxxx souhlas Parlament Xxxxx xxxxxxxxx.
Nové xxxxx Xxxxxxx X xxxxxxxxx x xxxxxxxx x souladu x xxxxxxx 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2013 x tímto xxxx xxxxxxxxx x platnost x pro Xxxxxx xxxxxxxxx. Dnem xxxxxx xxxxxx xxxxx Xxxxxxx X v xxxxxxxx xxxxxxxx xxxxxx xxxxx Xxxxxxx I Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx sportu xxxxxx xx 1. ledna 2012 a xxxxxxxxx xxx č. 97/2012 Sb. m. s.
Xxxxxxxx xxxxx Xxxxxxx X x xxxx xxxxxxx xx českého xxxxxx xx xxxxxxxxx současně.
1) Mezinárodní xxxxxx xxxxx xxxxxxx xx sportu xxxxxxx xxx 19. xxxxx 2005 x Xxxxxx xxxx xxxxxxxxx xxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
XXXXXXX X
XXXXXX XXXXXXXXXX LÁTEK X XXXXX XXXXXXX XXX ROK 2013
XXXXXXX XXXXXXXXXXXXX XXXXX
Xxxxxx xx 1. xxxxx 2013
Xxxxx xxxxxx 4.2.2 Světového xxxxxxxxxxxxxxx xxxxxx xxxxxxx Xxxxxxxx látky xxxxx xxxxxxxxxx xx "Specifické xxxxx" kromě xxxxx xx xxxxxx S1, X2, S4.4, S4.5 x X6(x) a Xxxxxxxxxx metod X1, X2 x X3.
| &xxxx;
XXXXX X METODY XXXXXXXX XXXXX
(XXX SOUTĚŽI X XXXX XXXXXX)
|
XXXXXXXX LÁTKY
X0. XXXXXXXXXXX XXXXX
Xxxxxxxxx xxxxxxxxxxxxx xxxxx, xxxxx xxxx xxxxxxxx x xxxxxxxxxxxxx sekcích Xxxxxxx x není aktuálně xxxxxxxxx pro xxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxx (např. xxxxxx x xxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx výzkumu xxxx xx xxxxxxxx xxxxxxxxxx, syntetické xxxxx, xxxxxxxxxxx xxxx), xx xxxxxxxx xxxxx.
X1. XXXXXXXXXX XXXXX
Xxxxxxxxxx xxxxx xxxx xxxxxxxx.
1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX):
(x) Xxxxxxxx* XXX, xxxxxxxxxx:
1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; xxxxxxxx; boldion (xxxxxxxx-1,4-xxxx-3,17-xxxx); danazol (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; xxxxxxxxxxxxx (19-xxx-17α-xxxxx-4-xx-17-xx); xxxxxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-hydroxy-17α-methylandrosta-1,4-dien-3-on); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); methyldienolon (17β-hydroxy-17α-methylestra-4,9-dien-3-on); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; xxxxxxxxxx (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxx; xxxxxxxxx; 19-xxxxxxxxxxxxxxxx (estr-4-en-3,17-dion); xxxxxxxxxx; xxxxxxxxxxxxxx; xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxxx; oxymesteron; xxxxxxxxxx; prostanozol (17β-xxxxxxx-5α-xxxxxxxxxx [3,2-x]xxxxxxx); xxxxxxxxx; stanozolol; xxxxxxxxx; 1-testosteron (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-homo-pregna-4,9,11-trien-17β-ol-3-on); xxxxxxxxx x xxxxx xxxxx x podobnou chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.
(x) Xxxxxxxxx** AAS, xxxxx xxxx xxxxxx xxxxxxxx:
Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA, 3ß-xxxxxxxxxxxxxx-5-xx-17-xxx), xxxxxxxxxxx a xxxxxx xxxxxxxxxx x xxxxxxx, xxx xx s xxxxxxxx xxxxx xx xx:
| &xxxx;
5α-xxxxxxxxx-3α,17α-xxxx
|
&xxxx;
5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx)
|
| &xxxx;
5α-xxxxxxxxx-3α,17β-xxxx
|
&xxxx; |
| &xxxx;
5α-xxxxxxxxx-3β,17α-xxxx
|
&xxxx;
xxx-xxxxxxxxxxxxxxxxxx
|
| &xxxx;
5α-xxxxxxxxx-3β,17β-xxxx
|
&xxxx;
xxxxxxxxxxxxxx
|
| &xxxx;
xxxxxxx-4-xx-3α,17α-xxxx
|
&xxxx;
3α-xxxxxxx-5αxxxxxxxxx-17-xx
|
| &xxxx;
xxxxxxx-4-xx-3α,17β-xxxx
|
&xxxx;
3β-xxxxxxx-5αxxxxxxxxx-17-xx
|
| &xxxx;
xxxxxxx-5-xx-3β,17α-xxxx
|
&xxxx;
7α-xxxxxxx-XXXX
|
| &xxxx;
xxxxxxx-5-xx-3α,17α-xxxx
|
&xxxx;
7β-xxxxxxx-XXXX
|
| &xxxx;
xxxxxxx-5-xx-3α,17β-xxxX
|
&xxxx;
7-xxxx-XXXX
|
| &xxxx;
xxxxxxx-5-xx-3β,17α-xxxx
|
&xxxx;
19-xxxxxxxxxxxxxx
|
| &xxxx;
4-xxxxxxxxxxxxx (androst-4-en-3β,17β-diol)
|
19-noretiocholanolon
|
2. Xxxxxxx anabolické xxxxx, xxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (SARM), xxxxxxx, xxxxxxx, zilpaterol, xxx xx x xxxxxxxx xxxxx xx ně.
|
Pro xxxxx xxxxxxx této xxxxx: * "xxxxxxxx" xx xxxxxxxx k xxxxx, xxxxxx xxxx xxxx normálně xxxxxxx xxxxxxxxxx přirozeně. ** "xxxxxxxxx " xx xxxxxxxx x látce, xxxxxx xxxx xxxx xxxxxxxxxx xxxxxxxxx.
|
X2. XXXXXXXXX HORMONY, XXXXXXX FAKTORY X XXXXXXXX LÁTKY
Následující xxxxx a xxxxxx xxxxxxxxxx faktory xxxx xxxxxxxx:
1. Xxxxx xxxxxxxxxxx xxxxxxxxxxx (xxxx. xxxxxxxxxxxx (XXX), xxxxxxxxxxx (xXXX), xxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx faktoru (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX), xxxxxxxxxxx /Xxxxxxxx/);
2. Xxxxxxxxxxxxxxxxxx (XX) a Xxxxxxxxxxxx hormon (LH) x mužů;
3. Xxxxxxxxxxxxxx;
4. Xxxxxxx xxxxxx (GH), xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXXx), xxxxxxxxxxxx xxxxxxx faktor (XXX), insulinu xxxxxxx xxxxxxx xxxxxx-1 (XXX-1), xxxxxxxxxx růstové xxxxxxx (XXX), růstový xxxxxx xxxxxxxx z krevních xxxxxxxx (XXXX) x xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx faktor (XXXX), xxxxxx xxxx xxxxxxxxx jiné xxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx xxxx degradaci bílkovin xxxxx, xxxxx x xxxxxx, xxxxxx xxxxxxxx, xxxxxxx xxxxxxx, regenerativní xxxxxxxx nebo ovlivňující xxxx xxxxxxxxx vláken;
x xxxxx xxxxx x podobnou chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.
S3. XXXX2- XXXXXXXX
Xxxxxxx xxxx-2 agonisté včetně xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx (např. x- x x-), xxxx xxxxxxxx kromě salbutamolu (xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx), xxxxxxxxxxx (maximálně 36 xxxxxxxxxx xx 24 xxxxx) x salmeterolu xxxxx xxxx podány x xxxxxxxx x xxxxxxx x doporučeným xxxxxxxx xxxxxxx xxxxxxx.
Xxxxxxxxxx xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx xxx 1000 xx/xx a xxxxxxxxxx xxxxxxxxxxx v xxxx x xxxxxxxxxxx vyšší xxx 40 ng/ml xxxxxx považována xx xxxxxxxxx terapeutické xxxxxxx, xxx xxxx považována xx xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx sportovec xxxxxxxxx kontrolovanou xxxxxxxxxxxxxxxxx xxxxxx, že xxxxxxxxxx xxxxxxxx byl xxxxxxxx xxxxxxxx xxxxxxxxxxxx inhalační xxxxx xxxxx xxx xxxx xxxxxxx xxxxxxx.
X4. XXXXXXXXX X XXXXXXXXXXX MODULÁTORY
Zakázané xx následující:
1. Xxxxxxxxxx aromatáz, zahrnující:
Xxxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-xxx),xxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxx ne x xxxxxxxx xxxxx xx xx.
2. Selektivní xxxxxxxxxx xxxxxxxxxxxxx receptorů (XXXX), xxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxx xx s xxxxxxxx xxxxx xx ně.
3. Ostatní antiestrogenní xxxxx zahrnující:
Xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxx xx s xxxxxxxx xxxxx xx xx.
4. Xxxxx xxxxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, ale xx x xxxxxxxx xxxxx xx xx.
5. Xxxxxxxxxxx xxxxxxxxxx:
x) Xxxxxxxx;
x) Xxxxxxxx delta aktivovaný xxxxxxxxxxxxxx proliferátory /Xxxxxxxxxx Xxxxxxxxxxxx Xxxxxxxxx Receptor δ (XXXXδ) xxxxxxxx/ (xxxx. XX 1516) x Xxxxxxxx xxxxxxxxxxxxxxx xxx xxxxxxxxxx AMP x xxxxxxxxxxx x XXXX xxxxx /PPARδ-AMP-activated xxxxxxx xxxxxx (XXXX) xxxx xxxxxxxx/ (např. XXXXX)
X5. XXXXXXXXX X OSTATNÍ MASKOVACÍ XXXXX
Xxxxxxxxx xxxxx xxxx xxxxxxxx. Xxxxxxxx:
Xxxxxxxxx, desmopressin, xxxxxxxxxxxxxxx (xxxx. xxxxxxxx, xxxxxxxxxx xxxxxx xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx x mannitolu), xxxxxxxxxx x xxxxx xxxxx x xxxxxxxxx xxxxxxxxxxxx xxxxxx. Xxxxxxx xxxxxx xxxxxxxxxxxx xxx xxxxx xxxxxxxx xxxx xxxxxxxx.
Xxxxxxxxx zahrnují:
Xxxxxxxxxxxx, xxxxxxxx, bumetanid, xxxxxxxxx, xxxxxxxxxxxx, indapamid, xxxxxxxx, xxxxxxxx etakrynová, xxxxxxxxx, spironolakton, xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx a xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými biologickými xxxxxx (xxxxx drospirenonu, xxxxxxxxx x xxxxxxxxx xxxxxx xxxxxxxxxxx x xxxxxxxxxxxx, xxxxx nejsou xxxxxxxx).
Pro xxxxxxx (Xxx Xxxxxxx, případně Xxxx Xxxxxx) xxxxxxxxxxx xxxxxxxx xxxxx xx xxxxxxxxxx prahovým limitem (xx. xxxxxxxxxx, salbutamol, xxxxxx, katin, xxxxxxx, xxxxxxxxxxxx a xxxxxxxxxxxxx) xx spojení s xxxxxxxxxx xxxx xxxxx xxxxxxxxx látkou je xxxxxxxxxx udělení xxxxxxxxxx Xxxxxxxxxxxx xxxxxxx na xxxx xxxxx xxxxx x xx, která xxx xxxx xxxxxxx xx xxxxxxxxxx xxxx xxxxx maskovací xxxxx.
XXXXXXXX XXXXXX
X1. MANIPULACE X XXXX X XXXXXXXX XXXXXXXXXXXX
Zakázané xx xxxxxxxxxxx:
1. Xxxxxx nebo znovuzavedení xxxxxxxxx, xxxxxxxxx xxxx xxxxxxxxxxx xxxx nebo xxxxxxxxx krvinek x xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxxx.
2. Xxxxx zvyšování xxxxxxxx, xxxxxxx xxxx dodávky xxxxxxx, xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx (xxxx.xxxxxx xxxxxxxx xxxxxxxx xx xxxxxxxxxxx, xxxxxxxxxxxxxxxxxx hemoglobiny), xxxxxxxxxxxxxxxxxxx a efaproxiral (XXX13), ale xx x omezením xxxxx xx ně. Xxxxxxxxxxxx xxxxxxxx xxxxxxxx není.
3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx s xxxx nebo x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx způsoby.
X2. CHEMICKÁ X XXXXXXXXX XXXXXXXXXX
Xxxxxxxx xx následující:
1. Xxxxxxxxx, xxxx pokus x podvod, xx xxxxxx porušit integritu x platnost Xxxxxx xxxxxxxxxx při Dopingové xxxxxxxx xx xxxxxxxx. Xx xxxxxxxx xxxxxx x/xxxx xxxxxx (např. xxxxxxxxxx) moči, xxx xx x xxxxxxxx xxxxx xx xx.
2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx xxxx xxx 50 xx xx 6 hodin xxxx zakázány xxxxx xxxxxx legitimně xxxxxxxxx x xxxxxxx nemocničních xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxx.
M3. XXXXXX XXXXXX
X xxxxxx xxxxxxxxxx ke xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxx následující:
1. Xxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxxx;
2. Xxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxxxx xxxxx;
| &xxxx;
XXXXX X METODY ZAKÁZANÉ XXX SOUTĚŽI
|
Xxxxx xxxxxxxxx X0 xx X5 x X1 až X3 xxxxxxxxx xxxx jsou Xxx Xxxxxxx xxxxxxxx x xxxxxxxxxxx skupiny:
XXXXXXXX XXXXX
X6. XXXXXXXXXXX
Všechna stimulancia xxxxxx všech jejich xxxxxxxxxx optických isomerů (xxxx. x- x x-) xxxx zakázaná, x xxxxxxxx xxxxxxxx xxxxxxxxx x xxxxxxx xxxxxx místního xxxxxxx x stimulancií zahrnutých xx Monitorovacího xxxxxxxx xxx xxx 2013*.
Xxxxxxxxxxx xxxxxxxx:
(a) Xxxxxxxxxxxx xxxxxxxxxxx:
Adrafinil, xxxxxxxxxx, xxxxxxxxxxx, amfetamin, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxx, fendimetrazin, xxxxxxxxx, fenfluramin, xxxxxxxx, xxxxxxxxxxx, fenproporex, xxxxxxxxx, 4-xxxxxxxxxxxxxx (xxxxxxxx), xxxxxxxxxx, xxxxxxxxxxx, kokain, kropropamid, xxxxxxxxxx, mefenorex, xxxxxxxxxxx, xxxxxxxxxxxx (x-), xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, mezokarb, modafinil, xxxxxxxxxxxxxx, x-xxxxxxxxxxxxxxx, prenylamin, xxxxxxxxx.
Stimulancium, xxxxx xxxx výslovně uvedeno x xxxxx odstavci, xx Xxxxxxxxxxx xxxxxx.
(x) Specifická xxxxxxxxxxx (xxxxxxxx):
Xxxxxxxxx**, katin***, xxxxxxx****, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, fenkamfamin, fenprometamin, xxxxxxxxxx, xxxxxxxxxxxx, levmetamfetamin, xxxxxxxxxxxx, xxxxxxxxxxxx****, xxxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), xxxxxxxxx, xxxxxxxxxxx, oktopamin, xxxxxxxxx, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxx, pseudoefedrin*****selegilin, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx a xxxxx látky s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
* Xxxxxxxxxxx xxxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2013 (xxxxxxxxx, fenylefrin, fenylpropanolamin, xxxxxx, xxxxxxx, pipradrol, xxxxxxxx) xxxxxx považovány xx Xxxxxxxx látky.
** Xxxxxxx podání xxxxxxxxxx (např. xxxxx, xxxx aplikace) xxxx xxxx podání xxxxxxxx x lokálními anestetiky xxxx xxxxxxxx.
*** Xxxxx xx zakázaný xxxxx xxx xxxxxxxxxxx xxxxx xxx 5 xxxxxxxxxx x 1 xx xxxx.
**** Xxxxxxx a methylefedrin xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxx xxx 10 xxxxxxxxxx x 1 xx xxxx.
***** Pseudoefedrin je xxxxxxx, xxxxx xxxx xxxxxxxxxxx v xxxx xx xxxxx než 150 xxxxxxxxxx xx xxxxxxxx
S7. XXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxxxxx, diamorfin(heroin), xxxxxxxx x jeho xxxxxxxx, hydromorfon, xxxxxxx, xxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx.
X8. XXXXXXXXXXX
Xxxxxxxx (xxxx. xxxxx, konopí a xxxxxxxxx) xxxx xxxxxxxxxx xxxxx9-xxxxxxxxxxxxxxxxxxx (XXX) a xxxxxxxxxxxxxx (xxxx. "Xxxxx" /XXX018, XXX073/ a XX-210) xxxx zakázané.
X9. GLUKOKORTIKOSTEROIDY
Všechny xxxxxxxxxxxxxxxxxxxx xxxxxxxx xxxxxx, xxxxxxxx, xxxxxxxxxx nebo xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxx.
| &xxxx;
XXXXX XXXXXXXX X XXXXXXXX XXXXXXXX
|
P1. ALKOHOL
Xxxxxxx (etanol) xx xxxxxxxx pouze Xxx Xxxxxxx v následujících xxxxxxxx. Xxxxxxx se xxxx provádět xxxxxxxx xxxxxxxx x/xxxx xxxxxxxx xxxx. Xxxxxxx xxxxxxx xxx xxxxxxxx dopingového xxxxxxxx (xxxxxxxxxxxxx xxxxxxx) xx 0.10 g/l.
∙ Xxxxxxxxxxxx sport (XXX)
∙ Xxxxxx (XXX)
∙ Xxxxxxx xxxxxx a xxxxxxxxxxxx(XXX)
∙ Xxxxxxxxxxx (FITA)
∙ Motocyklový xxxxx (XXX)
∙ Xxxxx xxxxxxxxxx (UIM)
P2. XXXX-XXXXXXXXX
Xxxxx xxxx xxxxx xxxxxx, xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx Xxx Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx.
∙ Xxxxxxxxxxxx sport (XXX)
∙ Xxxxxxxx (všechny xxxxxxxxxx) (XXXX)
∙ Xxxx (XXX)
∙ Xxxxxxxxxxx (XXXX, XXX) (xxxxxxxx také Mimo xxxxxx)
∙ Xxxxxxxx (XXX) - xxxxx xx lyžích a xxxxxxxxxxx lyžování-skoky a X-xxxxx,x xxxxxxxxx X-xxxxx x "big xxx"
∙ Xxxxxxx (XXXX, XXX) (zakázané xxxx Xxxx soutěž)
∙ Xxxxx (XXX)
Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx látky:
Xxxxxxxxxx, alprenolol, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxx, karteolol, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, metoprolol, nadolol, xxxxxxxxxx, pindolol, xxxxxxxxxxx, xxxxxxx, xxxxxxx, ale xx s xxxxxxxx xxxxx xx xx.
Informace
Xxxxxx xxxxxxx x. 98/2013 Xx. m. x. xxxxx xxxxxxxxx xxxx 20.12.2013.
Právní xxxxxxx x. 98/2013 Xx. m. x. xxx zrušen xxxxxxx xxxxxxxxx č. 47/2014 Sb. m. s. x xxxxxxxxx xx 20.9.2014.
Xxxxx jednotlivých xxxxxxxx xxxxx xxxxxx xxxxxxxx předpisů v xxxxxxxx xxxx aktualizováno, xxxxx xx xxxx xxxxxx derogační změna xxxxx xxxxxxxxx právního xxxxxxxx.